{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:10:12Z","timestamp":1773061812291,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Antipsychotic-induced catatonia is an iatrogenic and debilitating adverse reaction, but there is a dearth of recent documented cases. This report describes a 35-year-old incarcerated Korean-American male with a history of unspecified psychosis who presented for antipsychotic induced catatonia after administration of haloperidol decanoate intramuscular (200\u2009mg across the span of 1\u2009week). Neurologic workup was performed including MRI, lumbar puncture, and electroencephalography. Despite an approximate month long hospitalization, benzodiazepine challenge, benztropine trial, and amantadine adjunct, our patient continued to experience bradykinesia, waxy flexibility, and mask-like facies, and was minimally verbally responsive. Several challenges in the treatment of incarcerated individuals at the hospital are highlighted in this case report, including adverse reaction to medication, difficulty of care coordination, and limited access to health records among providers.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1092253","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:59:50Z","timestamp":1693483190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report on antipsychotic induced catatonia in an incarcerated patient"],"prefix":"10.3389","volume":"14","author":[{"given":"Han","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruslana","family":"Cannell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Rollakanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Seigler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia. I. Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/schbul\/sbx157","article-title":"Prevalence of catatonia and its moderators in clinical samples: results from a meta-analysis and meta-regression analysis","volume":"44","author":"Solmi","year":"2018","journal-title":"Schizophr Bull"},{"key":"ref3","unstructured":"2019"},{"key":"ref4","unstructured":"2023"},{"key":"ref5","first-page":"168","article-title":"What\u2019s in a name? The evolution of the nomenclature of antipsychotic drugs","volume":"27","author":"King","year":"2002","journal-title":"J Psychiatry Neurosci JPN"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1017\/S0790966700007497","article-title":"Antipsychotic drugs: atypical advantages and typical disadvantages","volume":"20","author":"Wright","year":"2003","journal-title":"Ir J Psychol Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/NDT.S147897","article-title":"Systematic review of catatonia treatment","volume":"14","author":"Pelzer","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/archpsyc.1977.01770200085010","article-title":"Catatonic reactions to high-potency neuroleptic drugs","volume":"34","author":"Gelenberg","year":"1977","journal-title":"Arch Gen Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00005053-198607000-00007","article-title":"Catatonic reaction to accidental haloperidol overdose: an unrecognized drug abuse risk","volume":"174","author":"Hoffman","year":"1986","journal-title":"J Nerv Ment Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000118713","article-title":"Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?","volume":"23","author":"Kontaxakis","year":"1990","journal-title":"Neuropsychobiology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00004583-199211000-00028","article-title":"Case study: neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome","volume":"31","author":"Woodbury","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1592\/phco.2005.25.8.1156","article-title":"Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome","volume":"25","author":"Tsai","year":"2005","journal-title":"Pharmacotherapy"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/jcp.0b013e3181c9bfe6","article-title":"Neuroleptic-induced catatonia","volume":"30","author":"Lee","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1017\/9781108975292","volume-title":"Prescriber\u2019s Guide: Stahl\u2019s Essential Psychopharmacology","author":"Stahl","year":"2021"},{"key":"ref15","unstructured":"2020"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1176\/ps.2007.58.6.782","article-title":"Treatment prospects for persons with severe mental illness in an Urban County jail","volume":"58","author":"Lamb","year":"2007","journal-title":"Psychiatr Serv"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(02)07740-1","article-title":"Serious mental disorder in 23\u2008000 prisoners: a systematic review of 62 surveys","volume":"359","author":"Fazel","year":"2002","journal-title":"Lancet"},{"key":"ref18","volume-title":"Psychiatric Services in Correctional Facilities","author":"Correctional","year":"2016"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09540261.2016.1248908","article-title":"Correctional mental health administration","volume":"29","author":"Tamburello","year":"2016","journal-title":"Int Rev Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1176\/appi.ps.202200041","article-title":"Communication over incarceration: improving care coordination between Correctional and community mental health services","volume":"73","author":"Morris","year":"2022","journal-title":"Psychiatr Serv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1345\/aph.1G297","article-title":"Catatonic schizophrenia and the use of memantine","volume":"40","author":"Carpenter","year":"2006","journal-title":"Ann Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1176\/jnp.2007.19.4.406","article-title":"Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes","volume":"19","author":"Carroll","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1124\/jpet.111.189076","article-title":"Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and Paliperidone","volume":"341","author":"Muly","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"ref24","unstructured":"2021"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1092253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:59:54Z","timestamp":1693483194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1092253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2023.1092253"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1092253","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1092253"}}